Eli Lilly Croissance future

Future contrôle des critères 5/6

Eli Lilly devrait augmenter ses bénéfices et son chiffre d'affaires de 29.5% et de 17.9% par an respectivement. Le BPA devrait croître de de 30% par an. Le rendement des capitaux propres devrait être 57.4% dans 3 ans.

Informations clés

29.5%

Taux de croissance des bénéfices

30.0%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	24.1%
Taux de croissance des recettes	17.9%
Rendement futur des capitaux propres	57.4%
Couverture par les analystes	Good
Dernière mise à jour	12 Nov 2024

Mises à jour récentes de la croissance future

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Nov 01

Recent updates

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Nov 01

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

Sep 18

Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside

Sep 04

Eli Lilly: Tirzepatide's Winning Streak Continues

Aug 20

Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)

Aug 12

Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic

Aug 04

Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China

Jul 25

A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)

Jul 16

Wall Street Lunch: Merger Monday In All Its Glory

Jul 08

5 Reasons Eli Lilly Just Keeps Rising

Jun 30

Prévisions de croissance des bénéfices et des revenus

NYSE:LLY - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	69,890	24,961	18,304	23,350	25
12/31/2025	58,321	19,654	12,124	17,923	28
12/31/2024	45,667	11,307	8,684	12,331	27
9/30/2024	40,863	8,370	-1,744	6,032	N/A
6/30/2024	38,923	7,342	-2,024	4,510	N/A
3/31/2024	35,932	6,138	-2,292	3,676	N/A
12/31/2023	34,124	5,240	-1,548	4,240	N/A
9/30/2023	32,073	4,988	1,469	6,215	N/A
6/30/2023	29,516	6,498	3,307	6,242	N/A
3/31/2023	27,691	5,687	3,881	6,793	N/A
12/31/2022	28,541	6,245	4,696	7,586	N/A
9/30/2022	29,240	6,033	5,404	8,080	N/A
6/30/2022	29,071	5,692	4,950	7,494	N/A
3/31/2022	29,323	6,129	5,824	8,086	N/A
12/31/2021	28,318	5,582	5,604	7,366	N/A
9/30/2021	27,759	5,972	4,621	6,919	N/A
6/30/2021	26,726	6,071	4,837	7,095	N/A
3/31/2021	25,486	6,093	5,565	7,815	N/A
12/31/2020	24,540	6,194	4,471	6,500	N/A
9/30/2020	23,214	5,573	5,112	6,648	N/A
6/30/2020	22,950	5,618	4,890	6,352	N/A
3/31/2020	23,087	5,533	3,684	4,908	N/A
12/31/2019	22,320	4,638	3,483	4,837	N/A
9/30/2019	21,843	4,264	2,671	4,322	N/A
6/30/2019	21,673	4,103	3,324	4,933	N/A
3/31/2019	21,622	2,545	2,217	5,399	N/A
12/31/2018	21,493	3,151	2,506	5,525	N/A
9/30/2018	22,016	372	2,100	5,819	N/A
6/30/2018	22,368	-166	N/A	5,579	N/A
3/31/2018	22,607	1,074	N/A	5,712	N/A
12/31/2017	19,974	-86	N/A	5,616	N/A
9/30/2017	22,471	2,225	N/A	5,879	N/A
6/30/2017	22,005	2,447	N/A	5,659	N/A
3/31/2017	21,585	2,187	N/A	5,410	N/A
12/31/2016	21,222	2,738	N/A	4,851	N/A
9/30/2016	20,837	2,444	N/A	3,841	N/A
6/30/2016	20,605	2,466	N/A	3,284	N/A
3/31/2016	20,179	2,319	N/A	2,830	N/A
12/31/2015	19,959	2,408	N/A	2,965	N/A
9/30/2015	19,704	2,359	N/A	3,318	N/A
6/30/2015	19,620	2,059	N/A	3,905	N/A
3/31/2015	19,577	2,192	N/A	4,010	N/A
12/31/2014	19,616	2,391	N/A	4,458	N/A
9/30/2014	20,303	2,690	N/A	4,744	N/A
6/30/2014	21,200	3,392	N/A	5,045	N/A
3/31/2014	22,194	3,865	N/A	5,628	N/A
12/31/2013	23,113	4,685	N/A	5,735	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de LLY ( 29.5% par an) est supérieure au taux d'épargne ( 2.6% ).

Bénéfices vs marché: Les bénéfices de LLY ( 29.5% par an) devraient croître plus rapidement que le marché US ( 15.5% par an).

Croissance élevée des bénéfices: Les bénéfices de LLY devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de LLY ( 17.9% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de LLY ( 17.9% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de LLY devrait être très élevé dans 3 ans ( 57.4 %).

Eli Lilly Croissance future

Future contrôle des critères 5/6

Informations clés

Mises à jour récentes de la croissance future

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 18%

Price target increased by 7.4% to US$989

Consensus EPS estimates increase by 16%

Price target increased by 7.2% to US$987

Recent updates

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next

Third quarter dividend of US$1.30 announced

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges

Eli Lilly and Company Announces Positive Results from the TRAILBLAZER-ALZ 6 Phase 3B Study

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly Buy On Weakness Signal (Technical Analysis)

Consensus EPS estimates fall by 18%

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis

Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)

Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside

Eli Lilly: Tirzepatide's Winning Streak Continues

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Price target increased by 7.4% to US$989

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Consensus EPS estimates increase by 16%

Price target increased by 7.2% to US$987

Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Upcoming dividend of US$1.30 per share

Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China

A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Wall Street Lunch: Merger Monday In All Its Glory

Eli Lilly and Company(NYSE:LLY) dropped from Russell 1000 Growth-Defensive Index

5 Reasons Eli Lilly Just Keeps Rising

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance